Cargando…

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder

Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Meng-Che, Huang, Cheng-Hua, Chiang, Po-Hui, Chen, Yen-Yang, Tang, Yeh, Su, Yu-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934043/
https://www.ncbi.nlm.nih.gov/pubmed/27390610
http://dx.doi.org/10.7150/jca.15213
_version_ 1782441273485950976
author Hsieh, Meng-Che
Huang, Cheng-Hua
Chiang, Po-Hui
Chen, Yen-Yang
Tang, Yeh
Su, Yu-Li
author_facet Hsieh, Meng-Che
Huang, Cheng-Hua
Chiang, Po-Hui
Chen, Yen-Yang
Tang, Yeh
Su, Yu-Li
author_sort Hsieh, Meng-Che
collection PubMed
description Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patients who were initially diagnosed to have mUCB and received MVAC or GC as metastatic first-line chemotherapy between 2000 and 2014 at Kaohsiung Chang Gung Memorial Hospital were reviewed. Totally, 130 patients were enrolled into our study. Univariable Cox proportional hazard models were constructed for OS. Hazard ratio (HR) and 95% confidence intervals (CIs) was also presented. Results: There were 50 patients (38%) in the MVAC group and 80 patients (62%) in the GC group. The median OS was insignificantly different between MVAC and GC groups, accounting for 17.0 and 14.4 months (P = 0.214), respectively. OS of MVAC group was significantly longer with regard to age ≦ 60 years (HR: 0.38, 95% CI: 0.12-0.97, P = 0.036), pure urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015), > 1 metastatic sites (HR: 0.19, 95% CI: 0.08-0.44, P = < 0.001), and neutrophil to lymphocyte ratio > 3(HR: 0.45, 95% CI: 0.25-0.81, P = 0.006), while OS with GC group was significantly longer with regard to variant urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015). Conclusions: Our study disclosed the predictive factors of different regimen for mUCB. These results have clinical implication for physicians who treat patients with mUCB.
format Online
Article
Text
id pubmed-4934043
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-49340432016-07-07 Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder Hsieh, Meng-Che Huang, Cheng-Hua Chiang, Po-Hui Chen, Yen-Yang Tang, Yeh Su, Yu-Li J Cancer Research Paper Purpose: Methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC) and gemcitabine plus cisplatin (GC) are both effective first-line chemotherapy. We explore the responsive variables of MVAC and GC for patients with metastatic urothelial carcinoma of bladder (mUCB). Materials and Methods: Patients who were initially diagnosed to have mUCB and received MVAC or GC as metastatic first-line chemotherapy between 2000 and 2014 at Kaohsiung Chang Gung Memorial Hospital were reviewed. Totally, 130 patients were enrolled into our study. Univariable Cox proportional hazard models were constructed for OS. Hazard ratio (HR) and 95% confidence intervals (CIs) was also presented. Results: There were 50 patients (38%) in the MVAC group and 80 patients (62%) in the GC group. The median OS was insignificantly different between MVAC and GC groups, accounting for 17.0 and 14.4 months (P = 0.214), respectively. OS of MVAC group was significantly longer with regard to age ≦ 60 years (HR: 0.38, 95% CI: 0.12-0.97, P = 0.036), pure urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015), > 1 metastatic sites (HR: 0.19, 95% CI: 0.08-0.44, P = < 0.001), and neutrophil to lymphocyte ratio > 3(HR: 0.45, 95% CI: 0.25-0.81, P = 0.006), while OS with GC group was significantly longer with regard to variant urothelial carcinoma (HR: 0.56, 95% CI: 0.34-0.90, P = 0.015). Conclusions: Our study disclosed the predictive factors of different regimen for mUCB. These results have clinical implication for physicians who treat patients with mUCB. Ivyspring International Publisher 2016-06-27 /pmc/articles/PMC4934043/ /pubmed/27390610 http://dx.doi.org/10.7150/jca.15213 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Hsieh, Meng-Che
Huang, Cheng-Hua
Chiang, Po-Hui
Chen, Yen-Yang
Tang, Yeh
Su, Yu-Li
Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title_full Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title_fullStr Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title_full_unstemmed Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title_short Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
title_sort tailored selection of first-line cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma of bladder
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934043/
https://www.ncbi.nlm.nih.gov/pubmed/27390610
http://dx.doi.org/10.7150/jca.15213
work_keys_str_mv AT hsiehmengche tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder
AT huangchenghua tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder
AT chiangpohui tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder
AT chenyenyang tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder
AT tangyeh tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder
AT suyuli tailoredselectionoffirstlinecisplatinbasedchemotherapyinpatientswithmetastaticurothelialcarcinomaofbladder